Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

• Status: Completed
• Trial end date: 2012-05-01

Summary

This study wants to determine the activity of a non chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabine-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced Non Small Lung Cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Aktion Bronchialkarzinom e.V.
• Collaborator: Roche Pharma AG
• Treatments: Bevacizumab; Cisplatin; Erlotinib Hydrochloride; Gemcitabine